Nasopharyngeal squamous cell carcinoma

disease

On this page

Summary

Nasopharyngeal squamous cell carcinoma (MONDO:0006060) is a cancer and 12 clinical trials. Top therapeutic interventions include cisplatin, atezolizumab, and cetuximab. A subtype of head and neck squamous cell carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

Classification: Cancer
Clinical trials: 12

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	nasopharyngeal squamous cell carcinoma
Mondo ID	MONDO:0006060
EFO	EFO:1000058
NCIT	C167265
UMLS	C0279698
MedGen	76017
GARD	0024279
Is cancer (heuristic)	yes

Disease family

This is a subtype of head and neck squamous cell carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › head and neck carcinoma › head and neck squamous cell carcinoma › nasopharyngeal squamous cell carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 12.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	5
PHASE1	3
PHASE2/PHASE3	2
EARLY_PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05063552	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
NCT03908372	PHASE2/PHASE3	UNKNOWN	Optimized Treatment Strategies for Early and Medium Stage Nasopharyngeal Carcinoma
NCT06532279	PHASE2	RECRUITING	Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
NCT06636734	PHASE2	RECRUITING	Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
NCT07135804	PHASE2	NOT_YET_RECRUITING	Iparomlimab and Tuvonralimab Injection for Untreated Locally Advanced Nasopharyngeal Carcinoma
NCT01596868	PHASE2	COMPLETED	GP VS TP in the Treatment of Advanced Nasopharyngeal Carcinoma in Northwest China
NCT04992988	PHASE2	UNKNOWN	Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial
NCT03803774	PHASE1	ACTIVE_NOT_RECRUITING	Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma
NCT06868433	PHASE1	RECRUITING	TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
NCT04870840	PHASE1	COMPLETED	Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer
NCT05245682	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer
NCT06662058	Not specified	RECRUITING	Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CISPLATIN	4	4
ATEZOLIZUMAB	4	1
CETUXIMAB	4	1
LOVASTATIN	4	1
BIRINAPANT	2	1
ASTX-660	1	1
CHEMBL5412235	0	1

Drugs: Cisplatin, Atezolizumab, Cetuximab, Lovastatin